Neurol. praxi. 2023;24(3):180-186 | DOI: 10.36290/neu.2023.035

Autoimmune leukoencephalopatis with predominant brain involvement

MUDr. Martin Elišák, Ph.D., MUDr. Hana Mojžišová, doc. MUDr. Aleš Tomek, Ph.D., FESO
Neurologická klinika 2. LF UK a FN Motol, Praha

Leukoencephalopathies can be difficult to diagnose. Diagnosis must focus on treatable causes. However, in addition to vascular, infectious and autoimmune causes, there are an increasing number of treatable genetic disorders. In the case of autoimmune encephalopathies, diagnosis and treatment have improved in recent years, allowing patients to be treated more quickly and effectively. Although there are still many unanswered questions about the mechanism by which the immune system attacks brain tissue, a better understanding of this mechanism will enable targeted immunotherapy to be chosen and prevent the possible worsening of the disease if the wrong treatment is applied. The aim of this article is to highlight the rarer inflammatory autoimmune leukoencephalopathies with predominant brain involvement, focusing on the targets and mechanisms of the immune response, and to help in the often difficult diagnosis of these entities.

Keywords: autoimmune leukoencephalopathy, differential diagnosis, CNS vasculitis, astrocytopathy, inflammatory vasculopathies, demyelinating diseases.

Received: May 3, 2023; Revised: May 23, 2023; Accepted: May 23, 2023; Prepublished online: May 23, 2023; Published: June 14, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Elišák M, Mojžišová H, Tomek A. Autoimmune leukoencephalopatis with predominant brain involvement. Neurol. praxi. 2023;24(3):180-186. doi: 10.36290/neu.2023.035.
Download citation

References

  1. Ainiala H, Hietaharju A, Loukkola J, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis & Rheumatism. 2001;45(5):419-23. Go to original source...
  2. Aringer M, Johnson SROV. New lupus criteria: a critical view. Current opinion in rheumatology. 2021;33(2):205-210. Go to original source... Go to PubMed...
  3. Auriel E, Charidimou A, Gurol ME, et al. Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy­‑Related Inflammation. JAMA neurology. 2016;73(2):197-202. Go to original source... Go to PubMed...
  4. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody­‑associated disease: International MOGAD Panel proposed criteria. Lancet neurology. 2023;23(3):268-282. DOI: 10.1016/S1474-4422(22)00431-8. Go to original source... Go to PubMed...
  5. Bonnan M, Berthelot E, Cabre P. Multiple sclerosis­‑like NMOSD patients suffer severe worsening of status after fingolimod initiation. Multiple sclerosis and related disorders. 2021;52:102975. Go to original source... Go to PubMed...
  6. Checa CM, Cohen D, Bollen ELE, et al. Demyelinating disease in SLE: Is it multiple sclerosis or lupus? Best Practice & Research Clinical Rheumatology. 2013;27(3):405-24. Go to original source... Go to PubMed...
  7. Dalmau J, Graus F. Autoimmune Encephalitis and Related Autoimmune Disorders of the Central Nervous System. 2022; XXXXXXX. Go to original source...
  8. Dörr J, Krautwald S, Wildemann B, et al. Characteristics of Susac syndrome: a review of all reported cases. Nature Reviews Neurology. 2013;9(6):307-16. Go to original source... Go to PubMed...
  9. Egan RA. Diagnostic Criteria and Treatment Algorithm for Susac Syndrome. Journal of neuro­‑ophthalmology: the official journal of the North American Neuro­‑Ophthalmology Society. 2019;39(1):60-67. Go to original source... Go to PubMed...
  10. Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta­‑analysis. BMC neurology.2016;16(1):220. Go to original source... Go to PubMed...
  11. Gastaldi M, Scaranzin S, Jarius S, et al. Cell­‑based assays for the detection of MOG antibodies: a comparative study. Journal of Neurology. 2020;267(12):3555-3564. Go to original source... Go to PubMed...
  12. Gastaldi M, Foiadelli T, Greco G, et al. Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study. Journal of neurology, neurosurgery, and psychiatry. 2022;94(3):201-210. Go to original source... Go to PubMed...
  13. Gravier­‑Dumonceau A, Ameli R, Rogemond V, et al. Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study. Neurology. 2022;98(6):e653-e668. Go to original source... Go to PubMed...
  14. Gross CC, Meyer C, Bhatia U, et al. CD8 T cell­‑mediated endotheliopathy is a targetable mechanism of neuro­‑inflammation in Susac syndrome. Nature communications. 2019;10(1):5779. Go to original source... Go to PubMed...
  15. Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. The Journal of rheumatology. 1992;19(5):732-741. Go to PubMed...
  16. Iorio R, Damato V, Evoli A, et al. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. Journal of neurology, neurosurgery, and psychiatry. 2018;89(2):138.146. Go to original source... Go to PubMed...
  17. Jarius S, Kleffner I, Dörr JM, et al. Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. Journal of neuroinflammation. 2014;11:46. Go to original source... Go to PubMed...
  18. Javed A, Reder AT. Therapeutic role of beta­‑interferons in multiple sclerosis. Pharmacology & Therapeutics. 2006; 110(1): 35-36. DOI: 10.1016/j.pharmthera.2005. 08. 011. Go to original source...
  19. Jennette JC, Charles Jennette J, Falk RJ, et al. Nomenclature of Vasculitides: 2012 Revised International Chapel Hill Consensus Conference. Systemic Vasculitides: Current Status and Perspectives. 2016;15-28. Go to original source...
  20. Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology. 2007;69(7):644-654. Go to original source... Go to PubMed...
  21. Jurynczyk M, Geraldes R, Probert F, et al. Distinct brain imaging characteristics of autoantibody­‑mediated CNS conditions and multiple sclerosis. Brain: a journal of neurology. 2017;140(3):617-627. Go to original source... Go to PubMed...
  22. Kidd DP. Sarcoidosis of the central nervous system: clinical features, imaging, and CSF results. Journal of neurology. 2018;265(8):1906-1915. Go to original source... Go to PubMed...
  23. Kleffner I, Dörr J, Ringelstein M, et al. Diagnostic criteria for Susac syndrome. Journal of neurology, neurosurgery, and psychiatry. 2016;87(12):1287-1295. Go to original source... Go to PubMed...
  24. Luessi F, Engel S, Spreer A, et al. GFAPα IgG­‑associated encephalitis upon daclizumab treatment of MS. Neurology(R) neuroimmunology & neuroinflammation. 2018;5(5):e481. Go to original source... Go to PubMed...
  25. Lu LX, Della­‑Torre E, Stone JH, et al. IgG4-related hypertrophic pachymeningitis: clinical features, diagnostic criteria, and treatment. JAMA neurology. 2014;71(6):785-793. Go to original source... Go to PubMed...
  26. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009; Go to original source...
  27. McKeon A, Pittock SJ, Lennon VA. CSF complements serum for evaluating paraneoplastic antibodies and NMO­‑IgG. Neurology. 2011;XXXX Go to original source...
  28. Miller DV, Salvarani C, Hunder GG, et al. Biopsy Findings in Primary Angiitis of the Central Nervous System. American Journal of Surgical Pathology. 2009;33(1):35-43. Go to original source... Go to PubMed...
  29. Nakayama M, Naganawa S, Ouyang M, et al. A Review of Clinical and Imaging Findings in Tumefactive Demyelination. AJR. American journal of roentgenology. 2021;1-12. Go to original source... Go to PubMed...
  30. Nikolopoulos D, Kitsos D, Papathanasiou M, et al. Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the 'Attikon' Lupus Cohort. Frontiers in Neurology. 2022;13. DOI: 10.3389/fneur.2022.889613. Go to original source... Go to PubMed...
  31. Nomenclature AADHCONNL and ACR AD HOC COMMITTEE ON NEUROPSYCHIATRIC LUPUS NOMENCLATURE (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis & Rheumatism.
  32. Piga M, Chessa E, Peltz MT, et al. Demyelinating syndrome in SLE encompasses different subtypes: Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmunity reviews. 2017;16(3):244-252. Go to original source... Go to PubMed...
  33. Salvarani C, Brown RD, Calamia KT, et al. Primary CNS vasculitis with spinal cord involvement. Neurology. 2008;70(24):2394-400. Go to original source... Go to PubMed...
  34. Salvarani C, Brown RD, Christianson T, et al. An Update of the Mayo Clinic Cohort of Patients With Adult Primary Central Nervous System Vasculitis. Medicine. 2015;94(21):e738. Go to original source... Go to PubMed...
  35. Sanna G, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. The Journal of rheumatology. 2003;30:985-92. Go to PubMed...
  36. Sarbu N, Alobeidi F, Toledano P, et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmunity Reviews. 2015;14(2):153-9. Go to original source... Go to PubMed...
  37. Theodoridou A, Settas L. Demyelination in rheumatic diseases. Postgraduate Medical Journal. 2008;84(989):127-32. Go to original source...
  38. Titulaer MJ, Höftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N­‑methyl­‑D-aspartate receptor encephalitis. Annals of neurology. 2014;75(3):411-428. Go to original source... Go to PubMed...
  39. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Annals of Neurology. 2006;59(3):566-9. Go to original source... Go to PubMed...
  40. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. Go to original source... Go to PubMed...
  41. Zardi EM, Giorgi C, Zardi DM. Diagnostic approach to neuropsychiatric lupus erythematosus: what should we do? Postgraduate medicine. 2018;130(6):536-547. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.